Drug intelligence / Profile preview

LCTA-3344

Development stage: Preclinical
Lead developer: National University of Pharmacy
Modality: Small Molecules

Overview

LCTA-3344 is a novel small molecule 1-substituted isatin-5-sulfonamide that acts as a potent apoptosis inducer. Developed for the treatment of breast cancer, it has demonstrated significant antiproliferative activity against both hormone-sensitive (MCF7) and hormone-resistant (MCF7/HT) breast cancer cell lines. Research indicates that LCTA-3344 induces apoptosis through a p53-independent mechanism, making it a promising candidate for overcoming endocrine resistance in breast cancer therapy. In preclinical studies, the compound showed a nearly twofold increase in activity against tamoxifen-resistant sublines compared to parental lines and exhibited strong synergistic effects when combined with AKT inhibitors, particularly AKT Inhibitor IV.

Other names: 1-substituted isatin-5-sulfonamide

Beyond the preview

Go deeper on LCTA-3344.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LCTA-3344.

Explore the full profile